Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy Correspondence

  

Authors:	Zeidan, A. M.; Fenaux, P.; Gobbi, M.; Mayer, J.; Roboz, G. J.; Krauter, J.; Robak, T.; Kantarjian, H. M.; Novák, J.; Jedrzejczak, W. W.; Thomas, X.; Ojeda-Uribe, M.; Miyazaki, Y.; Min, Y. H.; Yeh, S. P.; Brandwein, J. M.; Gercheva, L.; Demeter, J.; Griffiths, E. A.; Yee, K. W. L.; Issa, J. P. J.; Bewersdorf, J. P.; Keer, H.; Hao, Y.; Azab, M.; Döhner, H.
Title:	Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy
Journal Title:	Blood
Volume:	140
Issue:	3
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2022-07-21
Start Page:	285
End Page:	289
Language:	English
DOI:	10.1182/blood.2022015832
PUBMED:	35507690
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85134777585&doi=10.1182%2fblood.2022015832&partnerID=40&md5=6e87627d2bd1a9dd3d1fbea2ad563267
Notes:	Letter -- Export Date: 1 August 2022 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/196153